Tumour Registry Lung Cancer (TLK)

iOMEDICO

Status: Completed

Conditions: Lung Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT01192919

IOM TLK

Details and patient eligibility

About

Overview of treatment reality in patients with bronchial carcinoma requiring systemic treatment and being treated by office-based oncologists in Germany.

Full description

The TLK is a prospective, longitudinal, nation wide cohort study that collects data on the treatment reality of patients with NSCLC and SCLC. At inclusion, data in patient characteristics, comorbidities, tumor characteristics, biomarker testing and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. Patients are followed until death or for a maximum of 3 years.

Enrollment: 2,500 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• histologically confirmed Small Cell Lung Cancer (SCLC), Non Small Lung Cancer (NSCLC) or neuroendocrine tumors receiving therapy
• written informed consent
• start of neoadjuvant, adjuvant or first-line therapy no longer than 4 weeks before informed consent

Exclusion criteria

• patients not receiving any systemic therapy

Trial design

2,500 participants in 1 patient group

Patients with lung cancer

Description:

Patients with lung cancer requiring therapy